# A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)

> **NCT03435601** · PHASE2 · UNKNOWN · sponsor: **Josef Smolen, Univ. Prof. Dr.** · enrollment: 24 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Anifrolumab
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03435601
- **Lead sponsor:** Josef Smolen, Univ. Prof. Dr.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-18
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03435601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03435601, "A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03435601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*